RYAN SPECIALTY HOLDINGS, INC. current report, 31 July 2023

Full document

Ryan Specialty Holdings, Inc. Form 8-K Summary

Business Context and Reporting Period

Ryan Specialty Holdings, Inc. filed a Current Report on Form 8-K dated July 31, 2023. The filing reports corporate governance and director compensation matters under Item 5.02, along with related Regulation FD disclosure. It does not report quarterly or annual financial results.

Key Financial Metrics

The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating or financial performance metrics.

Material Changes

  • Francesca Cornelli was elected to the Board of Directors effective July 31, 2023.
  • Dr. Cornelli was appointed to the Audit Committee, and Henry S. Bienen was moved from the Audit Committee to the Compensation and Governance Committee.
  • The Board increased to twelve members.
  • The Board determined that Dr. Cornelli is independent under applicable New York Stock Exchange, Company, and Exchange Act Rule 10A-3 requirements.
  • Dr. Cornelli’s initial term expires at the 2024 annual meeting, subject to renomination and stockholder approval.

Compensation, Outlook, and Risks

  • Dr. Cornelli will participate in the standard non-employee director compensation arrangements.
  • She will receive restricted stock units with a grant-date fair value of $120,000, prorated for her service period. The RSUs fully vest on the grant date, with each unit representing one share of Class A common stock.
  • She will receive $85,000 annually in cash, paid quarterly, for Board service. No additional cash compensation will be paid for Audit Committee service.
  • The Company will enter into its standard form of indemnification agreement with Dr. Cornelli.
  • The filing states that no related-party transaction requiring disclosure under Item 404(a) was identified and that her selection was not pursuant to an arrangement or understanding with another person.
  • No financial guidance, business outlook, contingencies, unusual operating items, or material risk updates are provided.

Important Facts for Investors to Verify

  • Review the Company’s next periodic filing for any accounting impact from the new director’s RSU award and cash compensation.
  • Confirm Dr. Cornelli’s renomination and stockholder approval at the 2024 annual meeting.
  • Review Exhibit 99.1, the related July 31, 2023 press release, for any additional governance information.
  • Verify the final composition and committee assignments of the Board in subsequent filings.